Pernix Therapeutics Holdings Inc. (PTX) 4.78 $PTX
Pernix Therapeutics names Tasos Konidaris to board
M2 - Tue Apr 29, 6:04AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NasdaqGM
TX) revealed on Monday the addition of Tasos Konidaris as its non-executive director, chairman of the Audit Committee as well as a member of the board's Compensation Committee and the Nominating Committee.
Pernix Therapeutics Appoints Tasos Konidaris to Its Board of Directors
Business Wire - Mon Apr 28, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQTX), a specialty pharmaceutical company, today announced the appointment of Tasos Konidaris as a non-executive Director and as Chairman of the Audit Committee. Mr. Konidaris has served as Senior Vice President and Chief Financial Officer of Ikaria, Inc., a biotherapeutics company, since October 2011. Prior to joining Ikaria, since 2007, Mr. Konidaris served as Senior Vice President and Chief Financial Officer at Dun & Bradstreet (D&
Corporation, a leading commercial information services company. He was Principal Accounting Officer and led the Global Finance Operations of D&B beginning in 2005. From 2003 to 2005, Mr. Konidaris served as Group Vice President of the Global Pharmaceutical and Global Diversified Products Groups at Schering-Plough Corporation, a pharmaceutical company. Earlier in his career, Mr. Konidaris held senior financial and operational positions of increasing responsibility at the Pharmacia Corporation, Rhone-Poulenc Rorer, Novartis Corporation and Bristol-Myers Squibb Company. Mr. Konidaris holds an MBA from Drexel University, and a BS from Gwynedd Mercy College.
Pernix concludes sale of its Pernix Manufacturing Facility
M2 - Mon Apr 28, 3:06AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKTTX) revealed on Friday the completion of the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing (PML), including the mortgage associated with the facility.
Pernix Closes on Sale of Manufacturing Facility
Business Wire - Fri Apr 25, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that it has closed on the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML" to Woodfield Pharmaceutical LLC ("Woodfield".
3 Stocks Under $10 Moving Higher
at The Street - Fri Apr 25, 6:38AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 24, 12:28PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Pernix Therapeutics to Report First Quarter 2014 Financial Results on May 12, 2014
Business Wire - Mon Apr 21, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its first quarter 2014 financial results before the U.S. stock market opens on Monday, May 12, 2014 and has scheduled a conference call at 9:00 a.m. EDT that day to discuss the financial results.
Pernix Establishes New Corporate Headquarters
Business Wire - Thu Apr 17, 9:59AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced it has signed a lease for new corporate headquarters at 10 North Park Place in Morristown, NJ.
Super Stock Profits - Top Five Stocks in Focus: Constant Contact, Inc. Av Works Aviation Corporation, Pixelworks, Inc. Fannie Mae, Pernix Therapeutics Holdings
PR Newswire Europe - Thu Apr 10, 9:49AM CDT
LONDON, April 10, 2014 /PRNewswire/ --
Pernix Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 8:34AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that Pernix CEO Doug Drysdale is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 12:50 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
Pernix expects USD6.2m in net proceeds and annual cost savings from Pernix Manufacturing LLC's sale
M2 - Wed Apr 02, 5:28AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKTTX) said on Tuesday that it has entered into a definitive agreement to sell its Houston, TX-based manufacturing operations, Pernix Manufacturing LLC (PML).
Pernix Agrees to Divest Manufacturing Facility
Business Wire - Tue Apr 01, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKTTX), a specialty pharmaceutical company, today announced that it has signed a definitive agreement to divest its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML" to Woodfield Pharmaceutical LLC ("Woodfield".
Health Care Stocks on our Radar -- Research on Novo Nordisk, Tianyin Pharma, Pernix Therapeutics Holdings, and Oculus Innovative Sciences
PR Newswire - Wed Mar 26, 12:10PM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite finished at 4,234.27, up 0.19%. The Dow Jones Industrial Average closed the session at 16,367.88, up 0.56% and the S&P 500 ended the day at 1,865.62, higher by 0.44%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, and the same has gained 5.27% in the previous three months. Investor-Edge has initiated coverage on the following equities: Novo Nordisk A/S (NYSE: NVO), Tianyin Pharmaceutical Co. Inc. (NYSE MKT: TPI), Pernix Therapeutics Holdings (NASDAQ: PTX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS). Free technical research on NVO, TPI, PTX and OCLS can be downloaded upon signing up at:
Commit To Purchase Pernix Therapeutics Holdings At $5, Earn 24.1% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:19AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $5.66/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Pernix Therapeutics Appoints Senior Vice President of Sales and Marketing
Business Wire - Tue Mar 18, 9:35AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Rick Shalaby as Senior Vice President of Sales and Marketing effective March 17, 2014.
Pernix Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Mon Mar 17, 7:01AM CDT
--Quarter over Quarter Revenue Increased by 31.5% to $24 Million
Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
Pernix Therapeutics appoints Terence Novak as COO
M2 - Tue Mar 11, 6:24AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NasdaqGMTX) disclosed on Monday that Terence Novak has been elected as its chief operating officer.
Pernix Therapeutics Appoints Chief Operating Officer
Business Wire - Mon Mar 10, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of Terence Novak as Chief Operating Officer.
Pernix Therapeutics names Tasos Konidaris to board
M2 - Tue Apr 29, 6:04AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NasdaqGM
TX) revealed on Monday the addition of Tasos Konidaris as its non-executive director, chairman of the Audit Committee as well as a member of the board's Compensation Committee and the Nominating Committee. Pernix Therapeutics Appoints Tasos Konidaris to Its Board of Directors
Business Wire - Mon Apr 28, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ
TX), a specialty pharmaceutical company, today announced the appointment of Tasos Konidaris as a non-executive Director and as Chairman of the Audit Committee. Mr. Konidaris has served as Senior Vice President and Chief Financial Officer of Ikaria, Inc., a biotherapeutics company, since October 2011. Prior to joining Ikaria, since 2007, Mr. Konidaris served as Senior Vice President and Chief Financial Officer at Dun & Bradstreet (D& Corporation, a leading commercial information services company. He was Principal Accounting Officer and led the Global Finance Operations of D&B beginning in 2005. From 2003 to 2005, Mr. Konidaris served as Group Vice President of the Global Pharmaceutical and Global Diversified Products Groups at Schering-Plough Corporation, a pharmaceutical company. Earlier in his career, Mr. Konidaris held senior financial and operational positions of increasing responsibility at the Pharmacia Corporation, Rhone-Poulenc Rorer, Novartis Corporation and Bristol-Myers Squibb Company. Mr. Konidaris holds an MBA from Drexel University, and a BS from Gwynedd Mercy College. Pernix concludes sale of its Pernix Manufacturing Facility
M2 - Mon Apr 28, 3:06AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT
TX) revealed on Friday the completion of the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing (PML), including the mortgage associated with the facility. Pernix Closes on Sale of Manufacturing Facility
Business Wire - Fri Apr 25, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that it has closed on the sale of its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML" to Woodfield Pharmaceutical LLC ("Woodfield". 3 Stocks Under $10 Moving Higher
at The Street - Fri Apr 25, 6:38AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Nasdaq stocks posting largest percentage increases
AP - Thu Apr 24, 12:28PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Pernix Therapeutics to Report First Quarter 2014 Financial Results on May 12, 2014
Business Wire - Mon Apr 21, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its first quarter 2014 financial results before the U.S. stock market opens on Monday, May 12, 2014 and has scheduled a conference call at 9:00 a.m. EDT that day to discuss the financial results.
Pernix Establishes New Corporate Headquarters
Business Wire - Thu Apr 17, 9:59AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced it has signed a lease for new corporate headquarters at 10 North Park Place in Morristown, NJ. Super Stock Profits - Top Five Stocks in Focus: Constant Contact, Inc. Av Works Aviation Corporation, Pixelworks, Inc. Fannie Mae, Pernix Therapeutics Holdings
PR Newswire Europe - Thu Apr 10, 9:49AM CDT
LONDON, April 10, 2014 /PRNewswire/ --
Pernix Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 8:34AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that Pernix CEO Doug Drysdale is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 12:50 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector. Pernix expects USD6.2m in net proceeds and annual cost savings from Pernix Manufacturing LLC's sale
M2 - Wed Apr 02, 5:28AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT
TX) said on Tuesday that it has entered into a definitive agreement to sell its Houston, TX-based manufacturing operations, Pernix Manufacturing LLC (PML). Pernix Agrees to Divest Manufacturing Facility
Business Wire - Tue Apr 01, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKTTX), a specialty pharmaceutical company, today announced that it has signed a definitive agreement to divest its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML" to Woodfield Pharmaceutical LLC ("Woodfield". Health Care Stocks on our Radar -- Research on Novo Nordisk, Tianyin Pharma, Pernix Therapeutics Holdings, and Oculus Innovative Sciences
PR Newswire - Wed Mar 26, 12:10PM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite finished at 4,234.27, up 0.19%. The Dow Jones Industrial Average closed the session at 16,367.88, up 0.56% and the S&P 500 ended the day at 1,865.62, higher by 0.44%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, and the same has gained 5.27% in the previous three months. Investor-Edge has initiated coverage on the following equities: Novo Nordisk A/S (NYSE: NVO), Tianyin Pharmaceutical Co. Inc. (NYSE MKT: TPI), Pernix Therapeutics Holdings (NASDAQ: PTX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS). Free technical research on NVO, TPI, PTX and OCLS can be downloaded upon signing up at:
Commit To Purchase Pernix Therapeutics Holdings At $5, Earn 24.1% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:19AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $5.66/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Pernix Therapeutics Appoints Senior Vice President of Sales and Marketing
Business Wire - Tue Mar 18, 9:35AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Rick Shalaby as Senior Vice President of Sales and Marketing effective March 17, 2014. Pernix Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Mon Mar 17, 7:01AM CDT
--Quarter over Quarter Revenue Increased by 31.5% to $24 Million
Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
Pernix Therapeutics appoints Terence Novak as COO
M2 - Tue Mar 11, 6:24AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NasdaqGM
TX) disclosed on Monday that Terence Novak has been elected as its chief operating officer. Pernix Therapeutics Appoints Chief Operating Officer
Business Wire - Mon Mar 10, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of Terence Novak as Chief Operating Officer.
